Panchenko V M, Serebriakova T N, Podorol'skaia L V, Sorokoletov S M, Dzhanashiia P Kh
Eksp Klin Farmakol. 1995 May-Jun;58(3):28-31.
The oral use of the drug Piavit (derived from freeze-dried medicinal leeches) in 50 patients with coronary heart disease for 7 days in a daily dose of 600 mg (20 patients) and 1200 mg (30 patients) caused a moderate dose-independent increase in enzymatic, fibrinolysis, non-enzymatic fibrinolysis and antithrombin III activity. In half the patients who had low fibrinolytic levels, the agent stimulated mainly the release of plasminogen activator on administration days of 2 and 7. In other 15 patients the activity of plasminogen activator remained unchanged, but non-enzymatic fibrinolysis enhanced. Piavit prolonged the hypocoagulative effect of heparin and aspirin in the group of patients pretreated with these drugs. There were no clinical manifestations of the disease during 7 days.
对50例冠心病患者口服药物Piavit（源自冻干药用蚂蟥），连续7天，每日剂量为600毫克（20例患者）和1200毫克（30例患者），结果显示酶促纤溶、非酶促纤溶及抗凝血酶III活性出现中度的剂量非依赖性增加。在纤溶水平较低的半数患者中，该药物在给药第2天和第7天主要刺激纤溶酶原激活物的释放。在另外15例患者中，纤溶酶原激活物的活性保持不变，但非酶促纤溶增强。Piavit延长了肝素和阿司匹林对预先接受这些药物治疗患者组的低凝作用。在7天内未出现该疾病的临床表现。
